SCHEMBL2863255

SCHEMBL2863255

CC(=O)Nc1cc(F)c2[nH]nc(-c3cccc(F)c3)c2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTK P33981 4/20 0.47
NTRK1 P04629 2/20 0.45
ADORA3 P0DMS8 1/20 0.45
ADORA2A P29274 1/20 0.45
ADORA2B P29275 1/20 0.45
ADORA1 P30542 1/20 0.45
PLK4 O00444 1/20 0.45
PAK4 O96013 1/20 0.45
PTK2 Q05397 1/20 0.45
TBK1 Q9UHD2 1/20 0.45
MAPK8 P45983 2/20 0.44
CHEK1 O14757 1/20 0.42
FGFR1 P11362 1/20 0.42
NEK2 P51955 1/20 0.42
MAPK15 Q8TD08 1/20 0.42
TOP2A P11388 1/20 0.42
JAK3 P52333 1/20 0.41
MELK Q14680 1/20 0.41
PDE5A O76074 1/20 0.41
PDE1A P54750 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2868379 0.91 TTK (0.47) TTKNTRK1ADORA3ADORA2AADORA2B
SCHEMBL2867285 0.84 ITK (0.45) TTKMAPK8GSK3BITK
SCHEMBL2864323 0.81 MAP2K4 (0.51) NTRK1MAP2K4MAP2K7
SCHEMBL2863645 0.79 TTK (0.56) TTKMAPTSMN1; SMN2
SCHEMBL4345565 0.78 MAPK10 (0.47) ADORA3ADORA2AADORA2BADORA1MAPK8
SCHEMBL4341168 0.78 HPGDS (0.44) MAP2K4MAP2K7SMN1; SMN2GSK3AGSK3B
SCHEMBL4343139 0.78 POLB (0.49) ADORA3ADORA2AADORA1MAPTSMN1; SMN2
SCHEMBL2868575 0.78 POLB (0.45) TTKPLK4SMN1; SMN2
SCHEMBL4341030 0.78 HPGDS (0.44) MAP2K4MAP2K7SMN1; SMN2GSK3AGSK3B
SCHEMBL2861586 0.78 MAP2K4 (0.56) MAP2K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
CN-1300116-C 1H-indazole compounds EISAI CO LTD (JP) 2007-02-14 CN disclosed
US-6982274-B2 1H-indazole compound EISAI CO., LTD. (JP) 2006-01-03 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed
CN-1512987-A Novel 1H-indazole compound ������������ʽ���� 2004-07-14 CN disclosed
US-20040127538-A1 Novel 1h-indazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 TTK 1201/4885NTRK1 1241/4885ADORA3 1577/4885
US-20040127538-A1 Novel 1h-indazole compound MAPK1, MAPK14, MAPK3 TTK 1066/4885NTRK1 1387/4885ADORA3 2775/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 TTK 1201/4885NTRK1 1241/4885ADORA3 1577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.